It is possible that functional assays may guide clarification of risks in the future, as suggested by a recently published quantitative functional assay for CHEK2 missense variants, which suggested that variants demonstrating a similar functional impact to the R117G variant may confer the same level of cancer risk [27]. This evidence concerns the gene CHEK2 and cancer.